A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Si Chen
- Telefonnummer: 0518-82342973
- E-mail: si.chen@hengrui.com
Studiesteder
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210036
- First Affiliated Hospital With Nanjing Medical University (Jiangsu Province Hospital )
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Informed consent was obtained voluntarily
- Healthy males aged 18 ~ 45 years (inclusive)
- Body weight ≥50 kg, BMI 19 ~ 28 kg/m2 (inclusive)
- Adopt efficient contraceptive measures
Exclusion Criteria:
- Have a history of drug allergy, specific allergy, or allergic constitution
- Any previous or current medical history that may affect the safety of the participant in the trial or the course of the study drug in vivo
- Have a history of risk factors for torsade de pointes
- During the screening period, serum potassium, sodium, ALT, or AST were beyond the normal range, or the calculated eGFR was less than 90 mL/min/1.73m2
- During screening, 12-lead ECG showed atrioventricular block, atrial fibrillation or flutter, QTcF≥450 ms
- Chest X-ray findings deemed clinically significant by the investigator
- Have positive test results for hepatitis B surface antigen, hepatitis C virus antibody, or treponema pallidum antibody or nonnegative test result for human immunodeficiency virus (HIV) during the screening period
- Have used or are using any prescription or over-the-counter drugs within 2 weeks before the dosing
- Any drug that inhibits or induces hepatic drug-metabolizing enzymes within 4 weeks prior to administration
- All kinds of voiding disorders (such as frequent urination, dysuria, etc.), habitual constipation or diarrhea
- Workers engaged in conditions requiring long-term exposure to radioactivity; Or had significant radiation exposure (≥2 chest/abdominal CT scans, or ≥3 other types of X-ray examinations) within 1 year before the trial or had participated in a radiolabeled drug trial within 1 year
- Participants may have been unable to complete the study for other reasons or may have been deemed by the investigator to be unsuitable for enrollment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dose Level:A
Subject will receive [14C]HRS-9057 at dose level A
|
[14C]HRS-9057
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Total radioactivity recovery and cumulative total radioactivity recovery in urine and feces during each collection period
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Percentage of HRS-9057 parent drug and its metabolites in plasma relative to the total radioactivity exposure in plasma (%AUC)
Tidsramme: From Day 1 to Day 8
|
From Day 1 to Day 8
|
|
The percentage of HRS-9057 parent drug and its metabolites in urine and feces relative to the administered dose (%Dose)
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: Tmax
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: Cmax
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: t1/2
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: MRT
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: AUC
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: Tmax
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: Cmax
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: t1/2
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: MRT
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: AUC
Tidsramme: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Serious adverse events
Tidsramme: From ICF signing date to Day 28
|
From ICF signing date to Day 28
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HRS-9057-105
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .